Towards a universal disulphide stabilised single chain Fv format: importance of interchain disulphide bond location and vL-vH orientation.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Protein engineering, design & selection : PEDS

• Publication date

  2012-07-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1093/protein/gzs021PMID 22586154
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of Tetravalent, Bispecific CCR5 Antibodies with Antiviral Activity against CCR5 Monoclonal Antibody-Resistant HIV-1 Strains

  2011cited by this paper
• Engineering Anti-vascular Endothelial Growth Factor Single Chain Disulfide-stabilized Antibody Variable Fragments (sc-dsFv) with Phage-displayed sc-dsFv Libraries*

  2010cited by this paper
• A modular IgG-scFv bispecific antibody topology.

  2010influential reference
• Engineering of stable bispecific antibodies targeting IL-17A and IL-23.

  2009cited by this paper
• Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR

  2009cited by this paper
• The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators.

  2009cited by this paper
• Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.

  2009cited by this paper
• Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

  2008cited by this paper
• A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.

  2006cited by this paper
• Optimizing the Generation of Recombinant Single-Chain Antibodies Against Placental Alkaline Phosphatase

  2006cited by this paper
• Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility.

  2006cited by this paper
• Improved stability and yield of Fv targeted superantigen by introducing both linker and disulfide bond into the targeting moiety.

  2005cited by this paper
• Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability.

  2005cited by this paper
• Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody.

  2004cited by this paper
• Pharmacokinetics and biodistribution of genetically engineered antibodies.

  2002cited by this paper
• An efficient route to the production of an IgG-like bispecific antibody.

  2000cited by this paper
• Expression of a bispecific dsFv-dsFv' antibody fragment in Escherichia coli.

  2000cited by this paper
• Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity.

  1998cited by this paper
• Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment.

  1998cited by this paper
• Design and production of novel tetravalent bispecific antibodies

  1997cited by this paper
• Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer.

  1997cited by this paper
• A form of anti-Tac(Fv) which is both single-chain and disulfide stabilized: comparison with its single-chain and disulfide-stabilized homologs.

  1997cited by this paper
• Remodeling domain interfaces to enhance heterodimer formation

  1997cited by this paper
• Engineering antibody Fv fragments for cancer detection and therapy: Bisulfide-stabilized Fv fragments

  1996cited by this paper
• Thermal stabilization of a single‐chain Fv antibody fragment by introduction of a disulphide bond

  1995cited by this paper
• Preparation and characterization of a disulfide-stabilized Fv fragment of the anti-Tac antibody: comparison with its single-chain analog.

  1995cited by this paper
• Vl-linker-Vh orientation-dependent expression of single chain Fv-containing an engineered disulfide-stabilized bond in the framework regions.

  1995cited by this paper
• Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions.

  1994cited by this paper
• Recombinant anti-sialidase single-chain variable fragment antibody. Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex.

  1994cited by this paper
• Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3.

  1994cited by this paper
• Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv.

  1994cited by this paper
• Design of interchain disulfide bonds in the framework region of the Fv fragment of the monoclonal antibody B3

  1994cited by this paper
• A recombinant immunotoxin containing a disulfide-stabilized Fv fragment.

  1993cited by this paper
• A comparison of strategies to stabilize immunoglobulin Fv-fragments.

  1990cited by this paper
• Assembly of a functional immunoglobulin Fv fragment in Escherichia coli.

  1988cited by this paper
• Single-chain antigen-binding proteins.

  1988cited by this paper
• Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.

  1988cited by this paper

• Dual Targeting for Enhanced Tumor Immunity: Conditionally Active CD28xVISTA Bispecific Antibodies Promote Myeloid-Driven T-Cell Activation

  2025cites this paper
• Conditionally Active CD28xVISTA Bispecific Antibodies Promote Myeloid-Driven T-Cell Activation.

  2025cites this paper
• Design and engineering of bispecific antibodies: insights and practical considerations

  2024cites this paper
• A novel shark VNAR antibody-based immunotoxin targeting TROP-2 for cancer therapy

  2024cites this paper
• Prevention of Blood Incompatibility Related Hemagglutination: Blocking of Antigen A on Red Blood Cells Using In Silico Designed Recombinant Anti-A scFv

  2024cites this paper
• Molecular Dynamics-Based Design and Biophysical Evaluation of Thermostable Single-Chain Fv Antibody Mutants Derived from Pharmaceutical Antibodies

  2023cites this paper
• Next generation of multispecific antibody engineering.

  2023cites this paper
• ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype

  2023cites this paper
• “Stapling” scFv for multispecific biotherapeutics of superior properties

  2023cites this paper
• TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life

  2023cites this paper
• PD‐L1/TIGIT bispecific antibody showed survival advantage in animal model

  2022cites this paper
• Modern Advances in CARs Therapy and Creating a New Approach to Future Treatment

  2022cites this paper
• Tumor buster - where will the CAR-T cell therapy ‘missile’ go?

  2022cites this paper
• Nanobody-based CAR-T cells for cancer immunotherapy

  2022cites this paper
• Engineering an Enhanced EGFR Engager: Humanization of Cetuximab for Improved Developability

  2022cites this paper
• Arrangement of VL and VH Domains in VRC01-Based Chimeric Antigen Receptor (CAR) Affects Functions and Exhaustion Status of CAR-T Cells

  2021cites this paper
• Bispecific antibody target pair discovery by high-throughput phenotypic screening using in vitro combinatorial Fab libraries

  2021cites this paper
• Evolution of Escherichia coli Expression System in Producing Antibody Recombinant Fragments

  2020cites this paper
• Rapid and Effective Generation of Nanobody Based CARs using PCR and Gibson Assembly

  2020cites this paper
• Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization

  2020cites this paper
• Convenient method of producing cyclic single-chain Fv antibodies by split-intein-mediated protein ligation and chaperone co-expression.

  2020cites this paper
• Exploration and Modulation of Antibody Fragment Biophysical Properties by Replacing the Framework Region Sequences

  2020cites this paper
• Toward Drug-Like Multispecific Antibodies by Design

  2020cites this paper
• Novel TLR2xTLR4 Bispecific Antibody Inhibits Bacterial Sepsis

  2020cites this paper
• Human Hexa-Histidine-Tagged Single-Chain Variable Fragments for Bioimaging of Bacterial Infections

  2020cites this paper
• Conjugation of an scFab domain to the oligomeric HIV envelope protein for use in immune targeting

  2019cites this paper
• Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease

  2019cites this paper
• Cyclization of Single-Chain Fv Antibodies Markedly Suppressed Their Characteristic Aggregation Mediated by Inter-Chain VH-VL Interactions

  2019cites this paper
• Structural Changes in Stx1 Engineering Monoclonal Antibody Improves Its Functionality as Diagnostic Tool for a Rapid Latex Agglutination Test

  2018cites this paper
• Relative Contribution of Framework and CDR Regions in Antibody Variable Domains to Multimerisation of Fv- and scFv-Containing Bispecific Antibodies

  2018cites this paper
• The impact of structural biology in medicine illustrated with four case studies

  2017cites this paper
• Novel strategy for a bispecific antibody: induction of dual target internalization and degradation

  2016cites this paper
• Single Chain Variable Fragment Against Aβ Expressed in Baculovirus Inhibits Abeta Fibril Elongation and Promotes its Disaggregation

  2015cites this paper
• Structural design of disialoganglioside GD2 and CD3‐bispecific antibodies to redirect T cells for tumor therapy

  2015cites this paper
• Loop-sequence features and stability determinants in antibody variable domains by high-throughput experiments.

  2014cites this paper
• Heat-induced Irreversible Denaturation of the Camelid Single Domain VHH Antibody Is Governed by Chemical Modifications

  2014cites this paper
• Chemical Modifications the Camelid Single Domain VHH Antibody Heat-induced Irreversible Denaturation of Protein Structure and Folding :

  2014cites this paper
• Principles and engineering of antibody folding and assembly.

  2014cites this paper
• Development trends for generation of single-chain antibody fragments

  2014cites this paper
• Fab-PEG-Fab as a potential antibody mimetic.

  2013cites this paper
• Chemical and Genetic Modification

  2013cites this paper
• Immunotherapy of B-Cell Lymphoma with an Engineered Bispecific Antibody Targeting CD19 and CD5

  2013cites this paper